Sanofi India Ltd
NSE:SANOFI
Operating Margin
Sanofi India Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| IN |
|
Sanofi India Ltd
NSE:SANOFI
|
139.5B INR |
24%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
759.6B USD |
40%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
370.6B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.2T DKK |
45%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
208.7B CHF |
33%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
187.5B CHF |
33%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
165.9B GBP |
24%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
199.8B USD |
34%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
137.8B USD |
27%
|
Sanofi India Ltd
Glance View
Sanofi India Ltd., a prominent name in the pharmaceutical landscape, operates as a subsidiary of Sanofi S.A., the global healthcare giant headquartered in France. Its roots in India trace back to the early 1950s when it began importing and distributing vaccines. Over the decades, Sanofi India has evolved into a comprehensive provider of high-quality drugs, contributing significantly to the nation’s healthcare ecosystem. The company focuses primarily on therapeutic segments such as diabetes, cardiovascular diseases, oncology, and vaccines, boasting a robust portfolio of prescription medicines and over-the-counter products. By leveraging a vast network of healthcare professionals and engaging in continuous clinical research and development, Sanofi India ensures its position at the forefront of medical innovation, adhering to a global strategy of patient-oriented solutions and a commitment to improving health outcomes. Sanofi India's revenue model revolves around its diversified product portfolio, addressing a spectrum of critical health areas. The company generates income through the sale of its flagship products, which include insulin for diabetes management, anti-allergy medications, and innovative therapies for rare diseases, among others. While the domestic market plays a crucial role in its financial framework, Sanofi India also taps into international markets, exporting its high-quality pharmaceutical products across borders. The profitability of the company is further bolstered by its commitment to research and development, enabling it to introduce new drugs and therapies, thus continually expanding its market share. By maintaining strong distribution channels and fostering collaborations with medical institutions and regulatory bodies, Sanofi India ensures its products reach a broad consumer base, perpetuating its growth trajectory in the competitive pharmaceutical scene.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Sanofi India Ltd's most recent financial statements, the company has Operating Margin of 24%.
You don't have any saved screeners yet